Introduction
• Chronic myeloid leukaemia (CML) is a cancer of myeloid blood cells and represents around 15-20% of all leukaemias 1 • The disease has 3 phases: chronic (majority of patients), accelerated, blast (more advanced, difficult to treat)
• Imatinib, a tyrosine kinase inhibitor (TKI), was introduced in 2001 and has transformed the treatment of CML
• Following imatinib, three 2nd-generation TKIs have so far been appraised by NICE: dasatinib, nilotinib and most recently bosutinib Nilotinib (with PAS) found to be cost-effective compared to imatinib under both approaches, whilst dasatinib was dominated by nilotinib • Bosutinib was cost-effective vs HU under the surrogate approach, but not under the cumulative approach in a third-line CP CML population
• In all 3 appraisals, significant disparity in OS between approaches -why? Conclusion and Discussion
• The surrogate and cumulative survival approaches are associated with differing strengths and weaknesses, but both are associated with considerable uncertainty
• The choice of cumulative vs surrogate approach has a significant impact on the cost-effectiveness results and could change recommendations -By choosing one approach over another, one set of results is preferred over another -How is the choice made between the two options?
• Once an approach is taken in one disease area… -Should it be maintained for consistency? -Or replaced if superior approaches are found?
• Are there other examples (e.g. HIV) where structural assumptions have evolved within a certain disease area?
-Should existing coverage decisions be reviewed?
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Thank you! Any questions?
